Who Will Benefit from Psychedelic Medicine?

An essay based on my May 27 NIH/NCI talk: A Breast Cancer Patient’s Perspectives on the Uses of Psychedelics in Medicine

My psychedelic story began in 2012, when I was a subject in a clinical trial at Johns Hopkins University School of Medicine’s Behavioral Pharmacology Research Unit. I was given doses of psilocybin – the active ingredient in “magic mushrooms” to treat my cancer-related depression.

I’d become depressed after I’d moved to…

This post is for paid subscribers